Oculus Innovative Sciences (OCLS) Granted FDA 510(K) Approval for Microcyn Plus Wound Care Solution
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Oculus Innovative Sciences (NASDAQ: OCLS) was granted FDA 510 (k) okay for its Microcyn Plus Wound Care Solution.
|Device Classification Name||Dressing, Wound, Drug|
|Device Name||Microcyn Plus Wound Care Solution|
|Applicant Contact||Brian W. Martin|
|Correspodent Contact||Brian W. Martin|
|Classification Product Code|
|Decision||Substantially Equivalent (SESE)|
|510k Review Panel||General & Plastic Surgery|
|Reviewed By Third Party||No|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- UPDATE: Cvent, Inc. (CVT) Active on Reports of DOJ Probe into Deal
- Under Armour (UA) puts active onto Q3 and outlook
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!